JP2020512408A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020512408A5 JP2020512408A5 JP2020503373A JP2020503373A JP2020512408A5 JP 2020512408 A5 JP2020512408 A5 JP 2020512408A5 JP 2020503373 A JP2020503373 A JP 2020503373A JP 2020503373 A JP2020503373 A JP 2020503373A JP 2020512408 A5 JP2020512408 A5 JP 2020512408A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- naltrexol
- administered
- vitamin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 12
- JLVNEHKORQFVQJ-PYIJOLGTSA-N 6alpha-Naltrexol Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]1(O)CC[C@H]3O)CN2CC1CC1 JLVNEHKORQFVQJ-PYIJOLGTSA-N 0.000 claims 7
- 229930003316 Vitamin D Natural products 0.000 claims 4
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims 4
- 239000002246 antineoplastic agent Substances 0.000 claims 4
- 235000019166 vitamin D Nutrition 0.000 claims 4
- 239000011710 vitamin D Substances 0.000 claims 4
- 150000003710 vitamin D derivatives Chemical class 0.000 claims 4
- 229940046008 vitamin d Drugs 0.000 claims 4
- 229940123587 Cell cycle inhibitor Drugs 0.000 claims 2
- 230000036470 plasma concentration Effects 0.000 claims 2
- 238000011084 recovery Methods 0.000 claims 2
- PBCZSGKMGDDXIJ-HQCWYSJUSA-N 7-hydroxystaurosporine Chemical compound N([C@H](O)C1=C2C3=CC=CC=C3N3C2=C24)C(=O)C1=C2C1=CC=CC=C1N4[C@H]1C[C@@H](NC)[C@@H](OC)[C@]3(C)O1 PBCZSGKMGDDXIJ-HQCWYSJUSA-N 0.000 claims 1
- PBCZSGKMGDDXIJ-UHFFFAOYSA-N 7beta-hydroxystaurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3C(O)NC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(C)O1 PBCZSGKMGDDXIJ-UHFFFAOYSA-N 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 229950001573 abemaciclib Drugs 0.000 claims 1
- 229940041181 antineoplastic drug Drugs 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 230000032823 cell division Effects 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- HKSZLNNOFSGOKW-UHFFFAOYSA-N ent-staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(C)O1 HKSZLNNOFSGOKW-UHFFFAOYSA-N 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 239000002207 metabolite Substances 0.000 claims 1
- UZWDCWONPYILKI-UHFFFAOYSA-N n-[5-[(4-ethylpiperazin-1-yl)methyl]pyridin-2-yl]-5-fluoro-4-(7-fluoro-2-methyl-3-propan-2-ylbenzimidazol-5-yl)pyrimidin-2-amine Chemical compound C1CN(CC)CCN1CC(C=N1)=CC=C1NC1=NC=C(F)C(C=2C=C3N(C(C)C)C(C)=NC3=C(F)C=2)=N1 UZWDCWONPYILKI-UHFFFAOYSA-N 0.000 claims 1
- 229960004390 palbociclib Drugs 0.000 claims 1
- AHJRHEGDXFFMBM-UHFFFAOYSA-N palbociclib Chemical compound N1=C2N(C3CCCC3)C(=O)C(C(=O)C)=C(C)C2=CN=C1NC(N=C1)=CC=C1N1CCNCC1 AHJRHEGDXFFMBM-UHFFFAOYSA-N 0.000 claims 1
- HKSZLNNOFSGOKW-FYTWVXJKSA-N staurosporine Chemical compound C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1[C@H]1C[C@@H](NC)[C@@H](OC)[C@]4(C)O1 HKSZLNNOFSGOKW-FYTWVXJKSA-N 0.000 claims 1
- CGPUWJWCVCFERF-UHFFFAOYSA-N staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(OC)O1 CGPUWJWCVCFERF-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1704909.9A GB201704909D0 (en) | 2017-03-28 | 2017-03-28 | Cancer therapy |
| GB1704909.9 | 2017-03-28 | ||
| PCT/GB2018/050820 WO2018178668A1 (en) | 2017-03-28 | 2018-03-28 | A combination for use in the treatment of lung cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020512408A JP2020512408A (ja) | 2020-04-23 |
| JP2020512408A5 true JP2020512408A5 (enExample) | 2021-04-30 |
| JP7282072B2 JP7282072B2 (ja) | 2023-05-26 |
Family
ID=58688080
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020503373A Active JP7282072B2 (ja) | 2017-03-28 | 2018-03-28 | 肺がんの治療に使用するための組み合わせ |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US11304943B2 (enExample) |
| EP (1) | EP3600431B1 (enExample) |
| JP (1) | JP7282072B2 (enExample) |
| CN (1) | CN110740751A (enExample) |
| GB (1) | GB201704909D0 (enExample) |
| WO (1) | WO2018178668A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201308440D0 (en) * | 2013-05-10 | 2013-06-19 | Dalgleish Angus | Therapeutic |
| CN114533871A (zh) * | 2020-11-19 | 2022-05-27 | 中国科学院上海营养与健康研究所 | 靶向plk3在防治皮肤增生性疾病中的应用 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4689332A (en) | 1984-04-09 | 1987-08-25 | Research Corporation | Growth regulation and related applications of opioid antagonists |
| FR2759586B1 (fr) | 1997-02-20 | 2000-01-14 | Paul Trouillas | Medicament de type anticancereux comportant au moins a titre de principe actif du 1-alpha hydroxycalciferol ou alfacalcidol |
| CH693625A5 (it) | 1999-02-18 | 2003-11-28 | Inpharma Sa | Composizioni farmaceutiche contenenti composti ad attività promotrice di assorbimento di principi attivi. |
| US6384044B1 (en) | 1999-11-29 | 2002-05-07 | Bernard Bihari | Method of treating cancer of the prostate |
| CN1802349A (zh) | 2003-06-11 | 2006-07-12 | 诺瓦西股份有限公司 | 用活性维生素d化合物和其他治疗一起治疗肺癌 |
| CA2528519A1 (en) * | 2003-06-11 | 2005-02-24 | Novacea, Inc. | Treatment of lung cancer with active vitamin d compounds in combination with other treatments |
| AU2006235318A1 (en) | 2005-04-07 | 2006-10-19 | Hythiam, Inc. | Improved methods of and compositions for the prevention of anxiety, substance abuse, and dependence |
| KR20080042092A (ko) | 2005-07-27 | 2008-05-14 | 오렉시젠 세러퓨틱스 인크. | 체중감량 조성물 |
| CA2622684A1 (en) | 2005-09-30 | 2007-04-12 | Darrick Carter | Transdermal drug delivery systems, devices, and methods employing opioid agonist and/or opioid antagonist |
| US20090191185A1 (en) | 2006-04-26 | 2009-07-30 | The Uab Research Foundation | Reducing Cancer Cell Invasion Using an Inhibitor of Toll Like Receptor Signaling |
| US8623418B2 (en) * | 2007-12-17 | 2014-01-07 | Alpharma Pharmaceuticals Llc | Pharmaceutical composition |
| US8479760B2 (en) * | 2010-06-30 | 2013-07-09 | Easy Solutions Technologies, Inc. | Air conditioner water pan drain line system |
| JP2015107918A (ja) | 2012-02-14 | 2015-06-11 | 国立研究開発法人国立がん研究センター | 抗がん剤の作用を増強する医薬組成物、がん治療用キット、診断薬、及びスクリーニング方法 |
| JP2015531770A (ja) | 2012-08-29 | 2015-11-05 | サリックス ファーマシューティカルズ，インコーポレイテッド | 緩下剤組成物、ならびに便秘および関連胃腸疾患および症状を処置するための方法 |
| GB201410216D0 (en) | 2014-06-09 | 2014-07-23 | Cancer Vaccine Inst | Therapeutic |
| WO2016061531A1 (en) | 2014-10-17 | 2016-04-21 | Salix Pharmaceuticals, Inc. | Use of methylnaltrexone to attenuate tumor progression |
-
2017
- 2017-03-28 GB GBGB1704909.9A patent/GB201704909D0/en not_active Ceased
-
2018
- 2018-03-28 CN CN201880035454.9A patent/CN110740751A/zh active Pending
- 2018-03-28 WO PCT/GB2018/050820 patent/WO2018178668A1/en not_active Ceased
- 2018-03-28 US US16/499,168 patent/US11304943B2/en active Active
- 2018-03-28 EP EP18715907.4A patent/EP3600431B1/en active Active
- 2018-03-28 JP JP2020503373A patent/JP7282072B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009138003A5 (enExample) | ||
| FI3936130T3 (fi) | Valbenatsiinin annostusohjelma hyperkineettisten liikehäiriöiden hoitoon | |
| JP2012193216A5 (enExample) | ||
| JP2010525050A5 (enExample) | ||
| JP2017506624A5 (enExample) | ||
| RU2010133489A (ru) | Применение ингибиторов гамма-секретазы для лечения рака | |
| JP2013067645A5 (enExample) | ||
| JP2013155188A5 (enExample) | ||
| RU2017134443A (ru) | Способ лечения с применением традипитанта | |
| JP2019530706A5 (enExample) | ||
| JP2009542581A5 (enExample) | ||
| JP2013544290A5 (enExample) | ||
| MX380070B (es) | Una composición farmacéutica que comprende amlodipino, valsartán y rosuvastatina. | |
| JP2019526559A5 (enExample) | ||
| Paccaly et al. | Absence of clinically relevant drug interaction between delamanid, a new drug for multidrug-resistant tuberculosis (MDR-TB) and tenofovir or lopinavir/ritonavir in healthy subjects | |
| JP2020512408A5 (enExample) | ||
| RU2015127834A (ru) | Способы лечения диабета путем введения антагониста рецептора глюкагона в сочетании с ингибитором поглощения холестерина | |
| JP2013541587A5 (enExample) | ||
| JP2021505669A5 (enExample) | ||
| JP2014513121A5 (enExample) | ||
| RU2015139515A (ru) | Комбинированное лечение | |
| JP2014503589A5 (enExample) | ||
| JP2011500650A5 (enExample) | ||
| Meyers et al. | The efficacy and safety of valsartan in obese and non‐obese pediatric hypertensive patients | |
| JP2017515858A5 (enExample) |